Pirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA Monitoring
Pirche AG, a leader in digital molecular risk assessment, today announced a new collaboration to advance the field of transplant medicine and immunosuppression. In a strategic collaboration with Natera, Inc., a global leader in cell-free DNA testing and precision medicine, the companies aim to improve patient care by connecting pre-transplant immunological risk assessment with advanced post-transplant molecular monitoring using Natera’s Prospera™ test.
Under the terms of the collaboration, Pirche will drive customer education and interactions to highlight the clinical rationale of utilizing Pirche’s TxPredictor™ platform and pre-treatment risk stratification scores alongside Prospera test results.
The goal of the collaboration is to drive comprehensive, data-driven analysis of a patient’s immune status across the transplant journey and demonstrate the potential for more personalized transplant care. It combines Pirche’s ability to risk-stratify patients before transplantation, together with post-transplant monitoring performed with Prospera.
